SRPT
Sarepta Therapeutics, Inc.
Phase 3
Estimated
Eteplirsen
Muscular Dystrophy, Duchenne
T-minus 117 days
Oct 31, 2026
ClinicalTrials.gov
verified 13h ago
Countdown card →